Psilocybin for OCD: Evidence, Mechanism & Clinical Trials

What the Research Shows

OCD affects an estimated 1 in 40 adults in the US. Standard treatments — SSRIs and cognitive-behavioural therapy with exposure and response prevention (CBT/ERP) — produce remission in only 40–60% of patients. For the remainder, few options exist. This treatment gap has driven growing interest in psilocybin, which acts on the same serotonergic system implicated in OCD but through a fundamentally different mechanism than daily SSRIs.

How Psilocybin May Help OCD

Understanding psilocybin's potential in OCD requires understanding what goes wrong in OCD neurobiology. The condition is characterised by dysregulation of the cortico-striato-thalamo-cortical (CSTC) circuit — a neural feedback loop connecting the orbitofrontal cortex, caudate nucleus, thalamus, and anterior cingulate cortex. In OCD, this circuit becomes hyperactive and locked: intrusive thoughts trigger compulsive behaviours, which temporarily relieve anxiety, which reinforces the loop.

Why psilocybin may disrupt the CSTC loop

Psilocybin's active metabolite psilocin acts as a partial agonist at serotonin 5-HT2A receptors concentrated in the prefrontal cortex. Research from the Yale/Columbia trial team hypothesises three mechanisms:

• Normalisation of fronto-striatal connectivity — psilocybin may restore the hyperactive orbitofrontal-striatal signalling to a more balanced baseline
• Reduced anterior cingulate and amygdala reactivity — psilocybin appears to decrease activation of these regions in response to OCD-triggering stimuli, measured via fMRI at 48 hours post-dosing
• Neuroplasticity window — as with depression and PTSD, the neuroplasticity enhancement following a psilocybin session may allow entrenched compulsive thought patterns to be disrupted and restructured during post-session integration work

Clinical Trials: What's Been Done & What's Active

1. Moreno et al. (2006) — First Modern OCD Trial Emerging

Published in the Journal of Clinical Psychiatry, this was the first controlled clinical study of psilocybin in OCD patients. Nine participants received up to four single-dose exposures at sub-hallucinogenic to frankly hallucinogenic doses (25–300 µg/kg), in a modified double-blind design. All nine participants showed marked symptom decreases — ranging from 23% to 100% reductions on the Y-BOCS — in at least one session. Importantly, no significant dose-response relationship was found: lower doses sometimes produced results comparable to higher ones, a pattern that has since been replicated and raises questions about the mechanism.

2. Yale/Columbia RCT (2018–2024) — First Double-Blind Placebo-Controlled Trial Emerging

Led by Dr. Benjamin Kelmendi and Dr. Christopher Pittenger, this trial (NCT03356483) enrolled participants with treatment-refractory OCD — defined as having failed at least one adequate SSRI and/or CBT trial. Participants received a single moderate dose of psilocybin (0.25 mg/kg) or niacin as active placebo, with non-directive psychological support. The trial closed to enrollment in May 2024. Published results (Frontiers in Psychiatry, 2025) confirmed clinically significant mean reductions in OCD symptoms in the psilocybin group vs placebo at the 48-hour primary endpoint. Full quantitative results and follow-up data are anticipated in peer-reviewed publication in 2026.

3. Imperial College London (2025) — Pharmacological Challenge Early

Published in the Journal of Psychiatric Research (2025), this study administered two sequential doses of oral psilocybin (1 mg then 10 mg, four weeks apart) to patients with moderate-to-severe OCD. The 10 mg dose was well-tolerated and produced a rapid-onset moderate-to-large effect on compulsive symptoms, lasting up to one week after dosing. The authors note this study was limited by small sample size and absence of randomisation, and called for larger RCTs.

4. Yale Phase 2 Trial (Ongoing, 2026) Early

A second Yale trial (NCT05546658) is currently recruiting 30 participants for a double-blind, niacin-controlled study of 0.25 mg/kg psilocybin for treatment-refractory OCD, with an embedded fMRI component to measure fronto-striatal connectivity changes 48 hours post-dosing. This study will provide the first neural biomarker data on psilocybin's mechanism in OCD.

Psilocybin vs. Standard OCD Treatments

Standard first-line OCD treatment consists of two modalities: SSRIs (particularly fluvoxamine, sertraline, and fluoxetine at high doses) and cognitive-behavioural therapy with exposure and response prevention (CBT/ERP). Both have significant limitations.

The gap psilocybin is targeting

• SSRI response rates: approximately 40–60% of OCD patients respond to SSRIs; fewer than 20% achieve full remission (Soomro et al., 2008)
• CBT/ERP response rates: effective for 50–60% of patients who complete treatment, but dropout is high due to the distress of prolonged exposure exercises
• Treatment-resistant OCD: an estimated 25–40% of OCD patients fail both SSRIs and adequate CBT — this is the population psilocybin trials have focused on

All current psilocybin OCD trials require participants to discontinue SSRIs before dosing, due to the well-documented blunting effect of 5-HT2A receptor desensitisation. See Microdosing on SSRIs for the pharmacology of this interaction.

Who May Be a Candidate

Based on trial eligibility criteria, psilocybin for OCD has been studied in adults who meet the following profile:

• Confirmed DSM-5 diagnosis of OCD, established by clinical interview (MINI or equivalent)
• OCD of at least moderate severity on the Y-BOCS
• Failed at least one adequate trial of SSRI medication at therapeutic dose for ≥12 weeks
• Able and willing to discontinue SSRIs for the study period (under clinical supervision)
• No personal or family history of psychosis, schizophrenia, or bipolar I disorder
• No active suicidality, current substance use disorder, or significant cardiovascular disease

Access in 2026

Psilocybin is not FDA-approved for OCD and has not received Breakthrough Therapy designation for this indication. Legal access pathways in 2026 are limited:

Clinical trial enrollment

The primary legal access route. Active and recruiting trials can be found at clinicaltrials.gov — search "psilocybin OCD." Yale's ongoing Phase 2 trial (NCT05546658) is the most advanced US-based study currently recruiting. Participation is free; participants typically receive compensation for time and travel.

Oregon and Colorado licensed programs

Oregon and Colorado's state-licensed psilocybin programs permit supervised use by adults without requiring a specific diagnosis. While these programs are not clinical OCD treatment protocols, adults with OCD-related distress who do not qualify for trials may access supervised sessions through licensed facilitators in these states. This is not a medical treatment — it is supervised personal use within a legal framework. See Legal Status and Retreats for access details.

Planning a session? Psilocybin Therapy Guide covers the full three-phase protocol (preparation, dosing, integration) and the Integration Workbook covers post-session work. OCD-specific note: current trial protocols use non-directive supportive accompaniment during the psilocybin session — not OCD-specific exposure therapy. ERP work, where relevant, happens separately.

Frequently Asked Questions

Key Takeaways

• → Three independent trials now show psilocybin produces meaningful, rapid reductions in OCD symptoms — including a 2024 randomised, double-blind placebo-controlled trial at Yale/Columbia.
• → The proposed mechanism is CSTC circuit disruption — distinct from how SSRIs work — which may explain why some SSRI-refractory OCD patients respond to psilocybin.
• → A 2006 Arizona pilot found 23–100% reductions in Y-BOCS scores; a 2025 Imperial College study found moderate-to-large effects lasting up to one week after a 10 mg dose.
• → Psilocybin has no FDA Breakthrough Therapy designation for OCD. Clinical trial enrollment is the primary legal access pathway in 2026.
• → SSRIs must be discontinued before psilocybin dosing — 5-HT2A desensitisation from SSRIs significantly blunts effects. A supervised taper is required.